Kailera Therapeutics (NASDAQ:KLRA) Raised to Strong-Buy at TD Cowen

Kailera Therapeutics (NASDAQ:KLRA) was upgraded by analysts at TD Cowen to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other research firms have also recently issued reports on KLRA. Evercore assumed coverage on Kailera Therapeutics in a research report on Tuesday. They set an “outperform” rating for the company. JPMorgan Chase & Co. assumed coverage on Kailera Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $30.00 price objective for the company. Wall Street Zen raised Kailera Therapeutics to a “hold” rating in a research note on Saturday, April 25th. Leerink Partners initiated coverage on Kailera Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $36.00 price target for the company. Finally, Jefferies Financial Group initiated coverage on Kailera Therapeutics in a research note on Tuesday. They set a “buy” rating and a $48.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $42.75.

Kailera Therapeutics Stock Down 2.7%

KLRA stock opened at $22.30 on Tuesday. Kailera Therapeutics has a twelve month low of $20.86 and a twelve month high of $28.23.

Insider Buying and Selling

In other Kailera Therapeutics news, Director Andrew T. Kaplan bought 8,398,438 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the purchase, the director directly owned 26,255,581 shares in the company, valued at $420,089,296. This represents a 47.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Rtw Investments, Lp bought 500,000 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the completion of the purchase, the insider owned 10,776,820 shares in the company, valued at $172,429,120. The trade was a 4.87% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 10,460,938 shares of company stock worth $167,375,008 in the last ninety days.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.